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Dose Dependent Changes In The Crista
Neuroepitheium Resulting From Gentamicin
Ototoxicity In The Chinchilla
Abstract: This experiment was conducted to
investigate the dose-dependent effects of
gentamicin (GM) on the neuroepithelial
morphology of the posterior crista
ampullares (PCA) of the adult chinchilla.
The experiment focused on hair cell (HC)
morphology to monitor GM’s dose-dependent
effects and also to define an ototoxicallyefficient and safe dose what would
subsequently be used in a time course study.
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Chinchillas (n=13) were treated with
subcutaneous (SC) daily doses of 120 mg/kg,
60 mg/kg, and 30 mg/kg GM, respectively,
for six days. Light microscopy observations
were made from the excised PCA of two
animals from each group that survided the
complete treatment regimen plus one day
post-treatment (PT); these were compared
to an untreated control group (n=4).
Nephrotoxicity of GM was established by

Introduction
Historically, gentamicin (GM), an ototoxic
aminoglycoside antibiotic with high vestibular selectivity,
has been used in vestibular research mainly to induce
morphological change via its cochleo-vestibulotoxic
effects (1, 2, 3, 4, 5). The vestibulotoxic effect of GM on
hair cells proceeds through a cascade of irreversible,
biochemically disruptive events which may ultimately
result in death of these cells (6, 7). Interestingly, GM also
affects the proximal tubular cells in the kidney through
the same biochemical pathways, but the damage in this
case is temporary and is reversed through regeneration of
new epithelial cells over time (8, 9). We designed a study
to define a safe and efficient ototoxic dose to evaluate the
changes in the vestibular system hair cells and kidney
tubular cells of the chinchilla mammalian model. GM was
systemically administered to induce hair cell pathology in
the crista neuroepithelia (NE) of the chinchilla in order to

blood urea nitrogen (BUN) and creatinine
measurements. The 120 and 60 mg/kg doses
yielded a higher deterioration of kidney
function with elevated levels of BUN and
creatinine; pathological morphology within
the kidneys was also observed. These
findings were incompatible with the survival
of the animals. In addition, results from one
day post-treatment at each of the three
different doses revealed non-specific
morphological changes such as fusion of the
hairs of the cells, shrunken cytoplasm and
blebs. These results led us to choose the
lower, safer, yet ototoxically-efficient dose of
30 mg/kg to study the time course of the
GM-induced effects in a second experiment.
Key Words: Hair cells, gentamicin
ototoxicity, nephrotoxicity, crista ampullaris,
chinchilla

evaluate the dose-dependent changes. In addition,
histological kidney data documented neprotoxicity
supported definition of a efficient and safe otoxic dose for
further use in an another experiment. The specific
question that was addressed was: What are the changes
in the crista NE after different doses of GM?
Material and Methods
Adult chinchillas (Chinchilla Laniger), 8 to 12 months
of age, weighing 450-550 grams were utilized. Three
groups of animals (n=13) were treated with
subcutaneous (SC) daily doses of 120 mg/kg (n=5), 60
mg/kg (n=5), and 30 mg/kg (n=3), GM, respectively, for
six days. The animals were sacrificed on the first day after
the treatment. Observations were made from the PCA of
two animals from each group that survived the complete
treatment regimen plus one day post-treatment (PT). One

This work is supported by Grant NIDCD, DC011404-03. This was performed in accordance with the policy on human care of Laboratory Animals,
and the Animal Welfare Act (I. U. S. C et seq), the animal use protocol was appored by the Institutional Animal Care and Use Committee (IACUC) of
UCLA.
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of the objectives of this experiment was to determine a
GM dose that could be tolerated by the animals and
thereby effectively used to further study GM-induced NE
pathology. To assist in this objective, GM’s well-known
nephrotoxic effects were traced through measures of
blood urea nitrogen (BUN) and creatinine levels that were
determined from blood samples drawn at the time of
perfusion (n=21). Microscopic pathology of the kidneys
was also assessed.
Morphological Analysis
At the time of sacrifice for the surgical extraction of
the respective PCAs, animals were deeply anesthetized
(IM administration of a ketamine/xylazine mixture, 20
mg/kg & 3 mg/kg, respectively) and transcardially
perfused with 4% paraformaldehyde and 2%
glutaraldehyde (300 cc) after infusion of 0.9% NaCl (300
cc). Upon the completion of the perfusion, the temporal
bones and the kidneys were meticulously dissected out.
Otic capsules and the kidneys were soaked in 4%
paraformaldehyde and 2% glutaraldehyde solution in
separate vials. The tip of the cochlea was clipped and the
stapes were removed from the otic capsules. From these
sites, the vestibular end organs were gently perfused with

Figure 1.
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2% glutaraldehyde and 4% paraformaldehyde with a
micropipette under the dissecting microscope at least
three times during the 6 hours they were embedded in
the solution. Following dissection of the end organs,
these tissues were washed out three times (each ~15
minutes) with 0.1% phosphate buffer before and after
they were treated with 0.1% OsO4 for 45 minutes. Three
consecutive treatments of alcohol dehydration, each
lasting 10 minutes, were performed. For subsequent
analysis, the kidneys were embedded in paraffin blocks
and the end organs in plastic (araldite).
The cristae were cut vertically into 1µm thick sections
starting from the planum semilunatum (PS) to the center
(C) (300-500 µm) with the aid of an ultramicrotome
(MT2-B Dupont). To ensure a well-distributed sample
from each of the cristae, the first 5 sections of each 25
were mounted onto individual glass slides; the next 20
sections were discarded. This was repeated throughout
the entire first half of each crista (approximately 500
µms) as one half supplied more than an adequate amount
of sections for analysis. The PCA were stained with 0.1
% Toluidine Blue.
Paraffin embedded kidneys were cut into 25 µm
sections stained with hematoxilene-eosin. Both the PCAs
and kidneys were evaluated under light microscopy.

Potomicrograph of the PCA from a control animal showing the normal appearance of the sensory NE.
A circular shaped Type I (I) HC surrounded with a nerve calyx (straight arrow) and a type II (II) HC cylindrical in shape (curved arrow). The
basal lining of supporting cells (sc) exhibits a monolayer between this HC layer and stroma. Cuticular plates of the HCs facing the endolymphatic space are continuous (open arrows). Bundles of cilia can be observed across the surface of the crista (small arrows).
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Results
Morphology
Epithelium

of

the

Chinchilla

Vestibular

In mammals, the vestibular NE basically consists of
three types of cells. Type I and Type II HCs and the
supporting cells (Figure 1). The HCs are situated in the
upper two thirds of the NE. The HCs can be differentiated
into two groups in terms of their morphology and
innervation. Type I HCs are circular in shape and they are
surrounded with a herve calyx. More than one Type I HC
enveloped by one nerve calyx is common at the summits

of the crista in the more central regions (10, 11). Type II
HCs are rectangular in shape and they receive button
nerve endings. Stereocilia are the hairs of the cells that
face the endolymphatic lumen. The supporting cells are
basically cuboidal in shape with an ovoid nucleus; the
supporting cells exist as a monolayer in the lower one
third of the NE.10,11
Gentamicin Ototoxicity
The three different doses of GM used all rendered a
similar, non-specific morphology within the NE when
examined on the first day post-treatment. The NE

Figure 2.

Representative sections of the PCA of animals that
were treated with 120, (A), 60 (B) and 30 mg/kg (C)
GM. The NE shows similar morphology with the three
different doses. There are early signs of cell death
such as nuclear swelling (long arrows), HC cytoplasmic vacuolazation (open arrows) and shrinkage
(curved arrows). Cytoplasmic protrusions (small
arrows) and empty calyces (solid arrow) can be seen.
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Figure 3.

displayed HCs with vacuoles in the cytoplasm, apical
surface extrusions toward the endolymphatic space and a
few empty nerve calyces (Figure 2).
Gentamicin Nephrotoxicity
At the higher doses of GM, the kidney histopathology
revealed prominent proximal tubular damage (Figure 3)
whereas the 30 mg/kg dose appeared to induce less
damage to the proximal tubular epithelia. These
morphological observations correlated well with the
monitored blood levels of urea nitrogen and creatinine.
The results from the quantitative blood chemistry are
shown in Figure 4. Both BUN and creatinine levels were
found to be normal in blood samples from control
animals. Although the animals receiving the 30 mg/kg
dose of GM showed an initial, modest elevation in both
BUN and creatinine levels, these levels returned to control
values when monitored during the post-treatment period.
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Representative photomicrapraphs of
kidney from a control chinchilla (A)
and chinchilla treated with 120
mg/kg GM for six days (B).
Glomeruli (solid arrow), normal
proximal tubules (A, curved arrow)
and proximal tubular necrosis (B,
curved arrows) are seen.

Some of the animals expired shortly after (within 3-5
minutes) the GM injection on the third or fourth day of
treatment. These animals presented signs of acute
respiratory failure such as dyspnea or apnea.
Discussion
GM Ototoxicity
In the current study, all three doses of applied GM
(120, 60 and 30 mg/kg) yielded nonspecific changes in
the PCA NE on the first day after the complete treatment
regimen. The minimum dose to establish a clear ototoxic
effect is known to show intervariability between species
(12). Neurophysiological recordings in the cat determined
that a dose of 40 mg/kg of GM must be administered
daily for at least ten days to induce pathological
ototoxicity (13). Daily systemic administration of GM in a
dose range of 100-120 mg/kg for 10 days established
vestibulotoxicity in the guinea pig (14), whereas 30-60
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mg/kg/day for ten days is sufficient to produce ototoxic
effects in the squirrel monkey (15). In the chinchilla
however, our two highest doses, 60 and 120 mg/kg/day,
resulted in overwhelming mortality rates as early as third
or fourth day of treatment. However, administration of
A

30 mg/kg/day of GM induced similar pathology on the
first day PT. Therefore we believed that 30 mg/kg/day of
GM was an ototoxically efficient and ultimately safer dose
for further studies in this mammalian model (Figure 4).

B

Control BUN Levels

Post Treatment BUN Levels

250
200

_

150

_

100

_

50

_

20 mg/kg

_

0
0

30 mg/kg

0

5

0

4

7

Subjects #

0
1

2

3

4

5

Subjects #

Figure 4.

5
4
3
2
1
0

20 mg/kg
_

60 mg/kg

_
_

30 mg/kg

_
_

_

Creatinine mg/dl

0.2

_

_

_

0.4

_

Creatinine mg/dl

0.6

56

Post Treatment Creatinine Levels

D

0.8
_

2
Days

Control Creatinine Levels

C

_

0

60 mg/kg

4

_

_

_

_

20

BUN mg/dl

30

_

BUN mg/dl

40

7

21

56

Days

The results from the quantitative blood chemistry are shown in chart form. A and C show the control values for BUN and Creatinine. B and
D represent post–treatment values respectively in the chinchilla.

GM Nephrotoxicity
The reversible nephrotoxic side effect of this
aminoglycoside antibiotic is observed earlier than its
ototoxic effect7. The comatose symptoms observed in our
animals at the higher doses of GM most probably reflect
toxic levels of retained urea due to acute renal failure
and/or respiratory due to neuromuscular blockade.12
Rybak observed overwhelming systemic toxicity which
was incompatible with the survival of the animals when
he was investigating developmental ototoxicity in the
neonatal rats.16 GM’s dose-response relationship was
consistent with early deterioration of kidney function at
the higher doses in the current study. Evidence of
malfunctioning kidneys was confirmed with observed
morphological proximal tubular damage (Figure 3) and
increase in BUN and creatinine levels (Figure 4).
Respiratory failure due to neuromuscular blockade and
systemic toxicity are associated complications of
aminoglycoside-induced ototoxicity (4, 7, 8, 16, 17).

While we could not specifically determine whether
nephrotoxicity or GM-induced neuromuscular blockade
inidvidually caused the loss of animals at the higher doses
of GM, it is likely that both of these life-threatening
conditions were present and cooperating leading to the
observed symptoms.
In conclusion, systemic GM administration of 30, 60
and 120 mg/kg/day can induce similar morphological
changes in the crista NE of the chinchilla in the early
stages of toxicity. However, administrations of higher
doses display acute renal failure and/or neuromuscular
blockade resulting in inevitable loss of animals. Therefore,
we recommed 30 mg/kg/day dose as an efficient tool to
investigate ototoxicity in the chinchilla.
Corresponding author:
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